Omiganan

Star0

DB06610InvestigationalSmall molecule

Omiganan has been investigated for the treatment of Mupirocin-resistant MRSA skin infections.

Mechanism: Pharmacologically active on Cytoplasmic membrane
Curator reviewed
Primary indication: Investigated for use/treatment in bacterial infection and rosacea.Curator reviewed
Formula / weight: C₉₀H₁₂₇N₂₇O₁₂ · 1779.183 g/mol (avg)
Code names: CLS001 · CPI-226 · MBI 226 · MBI 594AN

Resolves to

Compound

UNII618SLL9VBSCAS204248-78-2ChEMBLCHEMBL1615933

Structure

InChIKeyMVPAMLBUDIFYGK-BHDRXCTLSA-NSMILES

[H]N=C(N([H])[H])N([H])CCC[C@H](N([H])C(=O)[C@H](CCCN([H])C(=N[H])N([H])[H])N([H])C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CN([H])C2=CC=CC=C12)N([H])C(=O)[C@H](CCCN([H])C(=N[H])N([H])[H])N([H])C(=O)[C@H](CC(C)C)N([H])C(=O)[C@@H](N([H])[H])[C@@H](C)CC)C(=O)N([H])[C@@H](CCCCN([H])[H])C(=O)N([H])[H]

What you can answer from here — as of September 22, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Omiganan, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account